3 years 0
Extreme 1.0E-6
0
5 years 0
Extreme 1.0E-6
0
10 years 0
Extreme 1.0E-6
0.05
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 33
+0.66%+1.83%+47.32%+97.63% 69.69B
+1.63%+0.75%+37.47%+76.61% 61.24B
+1.25%-2.13%-13.96%+369.19% 26.77B
+0.32%+5.47%+27.74%+14.91% 26.12B
+3.26%+2.87%+1.04%-9.05% 24.07B
+1.76%+7.92%+27.08%-13.64% 20.39B
0.00%-10.41%+171.96%+298.75% 15.72B
+1.34%-0.08%+41.90%+168.78% 14.07B
+0.17%-2.74%-9.79%+455.90% 14.03B
Average +1.09%-0.40%+36.75%+162.12% 30.23B
Weighted average by Cap. +1.23%+0.51%+35.56%+127.67%
Logo ARYx Therapeutics, Inc.
ARYx Therapeutics, Inc. is a United States-based pharmaceutical Company. The Company is developing a proprietary portfolio of patient-targeted, first-in-class monoclonal antibodies designed to treat seriously ill patients with difficult-to-treat diseases. It is engaged in retrometabolic drug design that focuses on the safety of oral therapies for chronic disease. The Companys clinical compounds include naronapride (ATI-7505) for gastrointestinal disorders; budiodarone (ATI-2042, for the treatment of atrial fibrillation; tecarfarin (ATI-5923) for the treatment of anticoagulation; and ATI-9242, for psychiatric disorders.
Employees
56
  1. Stock Market
  2. Stocks
  3. ARYX Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!